Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTOF), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc. (APTOF) is a clinical-stage precision oncology company focused on developing small molecule therapies for hematologic cancers, particularly acute myeloid leukemia (AML). The news flow around Aptose centers on the clinical progress of its lead oral kinase inhibitor tuspetinib (TUS), corporate financing arrangements, and a planned acquisition by Hanmi Pharmaceutical Co. Ltd.
Investors following APTOF news will see regular updates on the TUSCANY Phase 1/2 trial, where tuspetinib is combined with standard dosing of venetoclax and azacitidine (TUS+VEN+AZA) as a triple drug frontline therapy for newly diagnosed AML patients ineligible for induction chemotherapy. Company press releases highlight safety data, complete remission (CR/CRh) rates, minimal residual disease (MRD) negativity, and responses across diverse genetic subtypes, including patients with adverse mutations such as TP53, RAS, FLT3-ITD, NPM1c, and myelodysplasia-related mutations.
The Aptose news stream also includes quarterly financial results, where management discusses research and development spending by program, cash position, and reliance on loan facilities from Hanmi to fund operations. Additional items include announcements of conference presentations at major meetings such as the European Hematology Association (EHA), the European School of Haematology (ESH), and the American Society of Hematology (ASH), where new clinical data from TUSCANY are presented.
Another key category of news involves transaction and governance updates. Aptose has announced an arrangement agreement under which a Hanmi subsidiary will acquire all outstanding common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. The company also reports outcomes of shareholder meetings and changes in its independent auditor. For readers tracking APTOF, this news page provides a consolidated view of clinical, financial, and corporate developments disclosed by the company.
Aptose Biosciences (OTC: APTOF) reported a further delay in closing its plan of arrangement with Hanmi Pharmaceutical as Korean regulatory approvals are still in progress. The parties now target closing in June and do not expect the review to prevent completion.
On closing, Hanmi will acquire all Aptose common shares it does not already own for C$2.41 in cash per share, a 28% premium to the prior 30‑day VWAP of C$1.88. Aptose also received an additional US$2.0 million advance under an US$11.9 million loan facility, bringing total advances to US$9.9 million, with a final US$2.0 million expected soon. These funds support ongoing operations and the TUSCANY clinical trial of tuspetinib plus venetoclax and azacitidine for newly diagnosed AML.
Aptose (OTC:APTOF) reported Q1 2026 results and a corporate update. Net loss was $7.6 million on operating expenses of $7.2 million. Cash stood at $4.1 million, and the company states it relies on Hanmi advances while pursuing cost reductions.
The planned acquisition by Hanmi Pharmaceutical remains pending Korean regulatory approvals, with closing targeted for May. Shareholders are to receive C$2.41 per share, a 28% premium to the 30‑day VWAP. Updated tuspetinib TUSCANY trial data will be presented in an oral session at EHA 2026.
Aptose Biosciences (OTC: APTOF) said closing of its previously announced Plan of Arrangement with Hanmi Pharmaceutical has been delayed while certain Korean regulatory approvals remain in progress.
The parties continue to work toward completion and now target closing in May 2026. Upon completion, Hanmi will pay C$2.41 per share (a 28% premium to Aptose's 30‑day VWAP).
Aptose (OTC: APTOF, TSX: APS) announced shareholder approval of a C$2.41-per-share cash go-private arrangement with Hanmi, and final court approval from the Court of King’s Bench of Alberta. Closing is expected by end of April 2026, subject to customary conditions and regulatory approvals.
Clinical data for the TUS+VEN+AZA triplet showed high response rates and 78% MRD-negativity by central flow cytometry; year-end cash was $4.1M with long-term liabilities of $27.9M, and net loss of $25.5M for 2025.
Aptose (OTC: APTOF) amended its arrangement agreement with Hanmi, reconvening the special meeting to March 31, 2026 and setting the record date as February 24, 2026. The company filed a definitive proxy statement and will continue corporate continuance to Alberta before completing a statutory arrangement.
Financing: Aptose entered a US$11.1 million amended facility with Hanmi (uncommitted, advances through May 31, 2026), interest at 6% per annum; first advance expected soon.
Aptose Biosciences (OTC: APTOF) has rescheduled its special meeting of shareholders originally set for January 16, 2026 to a later date in January 2026 to be announced. The company said the meeting is being rescheduled so Aptose can first obtain final SEC clearance of the proxy statement.
No change is expected to the record date (close of business on December 12, 2025) or the matters before shareholders, including the Continuance to Alberta law and the proposed acquisition by HS North America Ltd., a Hanmi Pharmaceutical subsidiary, by way of a statutory plan of arrangement (the Transaction). Aptose obtained an interim court order authorizing the meeting on December 12, 2025, and the board unanimously recommends voting FOR the Continuance and Arrangement. Proxy materials will be mailed and filed on SEDAR+ and EDGAR after SEC clearance.
Aptose (NASDAQ: APTOF) reported updated TUSCANY trial data showing that tuspetinib (TUS) combined with venetoclax (VEN) and azacitidine (AZA) produced high frontline responses in newly diagnosed AML patients ineligible for induction chemotherapy.
Key metrics: CR/CRh 90% across 40/80/120 mg cohorts and 100% CR/CRh at the 80 mg and 120 mg TUS dose levels; MRD-negativity 78% by central flow cytometry in responders. No dose-limiting toxicities were reported across evaluable dose levels, and no drug-related deaths, differentiation syndrome, QTc prolongation, or CPK elevations were observed.
Notable safety and subgroup signals include responses across FLT3-WT, FLT3-ITD, NPM1c, biallelic TP53/complex karyotype, RAS, and MDS-related mutations, and transfusion independence in 8/10 evaluable subjects.
Aptose Biosciences (OTC: APTOF; TSX: APS) agreed to be acquired by Hanmi Pharmaceutical for C$2.41 per common share in a going-private plan of arrangement announced Nov 19, 2025. The price represents a 28% premium to Aptose’s 30-day VWAP of C$1.88 on the TSX. Hanmi currently owns 19.93% of Aptose and provided over US$30 million of debt support to develop tuspetinib (TUS).
Transaction conditions include court and shareholder approval (special meeting by Jan 16, 2026), customary closing conditions, and delisting and cessation of public reporting on closing. Locust Walk valued Aptose between C$1.00–C$5.23 and delivered a fairness opinion. Option, RSU and warrant holders will receive cash consideration or Black‑Scholes cash settlement for Armistice warrants. A C$300,000 termination fee is payable in certain circumstances.
Aptose (OTC: APTOF) reported Q3 2025 results and clinical updates on tuspetinib. Financially, Q3 net loss narrowed to $5.1M (Q3 2024: $7.0M) and nine‑month net loss was $17.7M (YTD 2024: $23.8M). Cash and equivalents were $1.6M as of Sept 30, 2025, and the company says it lacks sufficient cash to fund operations and relies on advances from Hanmi while pursuing financing and cost reductions.
Clinically, TUSCANY triplet data show strong activity: CR/CRh in 6/6 (100%) patients at 80 mg and 120 mg tuspetinib, overall 9/10 (90%) responses across dose cohorts, MRD‑negativity in 7/9 (78%) responders, HSCT completed in 2 patients, and dose escalation to 160 mg underway; an ASH poster was accepted for Dec 2025 presentation.
Aptose (APTOF) announced that an abstract from its TUSCANY study of tuspetinib combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) has been selected for a poster presentation at the 67th ASH Annual Meeting, December 6-9, 2025 in Orlando.
The poster titled TUSCANY Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy (Publication #1645) will be presented on December 6, 2025, 5:30–7:30 PM in OCCC West Halls B3-B4. The abstract appears on the ASH website and in the November supplemental issue of Blood, and the poster will be posted on Aptose's website. Aptose noted the live presentation will include more recent updates and additional data beyond the abstract.